Patient, disease, and transplantation characteristics
| Characteristic . | n (%) . | P . | |
|---|---|---|---|
| HLA-haploidentical donor (N = 176) . | HLA-matched unrelated donor (N = 427) . | ||
| Age, y | <.001 | ||
| 50-59 | 38 (22) | 41 (10) | |
| 60-69 | 103 (59) | 250 (59) | |
| 70-79 | 35 (20) | 136 (32) | |
| Sex | .24 | ||
| Male | 123 (70) | 277 (65) | |
| Female | 53 (30) | 150 (35) | |
| Race | <.001 | ||
| White | 141 (80) | 405 (95) | |
| Non-White | 32 (18) | 14 (3) | |
| Not reported | 3 (2) | 8 (2) | |
| HCT-CI | .30 | ||
| 0-2 | 76 (43) | 165 (39) | |
| 3+ | 100 (57) | 262 (61) | |
| KPS | .004 | ||
| 90-100 | 87 (49) | 177 (42) | |
| <90 | 82 (47) | 246 (57) | |
| Not reported | 7 (4) | 4 (< 1) | |
| CMV serostatus | .22 | ||
| Negative | 58 (33) | 173 (41) | |
| Positive | 117 (66) | 252 (59) | |
| Not reported | 1 (<1) | 2 (<1) | |
| Disease type | .44 | ||
| De novo MDS | 152 (86) | 358 (84) | |
| Therapy-related MDS | 24 (14) | 69 (16) | |
| WHO classification | .02 | ||
| RA/RARS/RCMD | 39 (22) | 134 (31) | |
| RAEB-1/RAEB-2 | 97 (55) | 229 (54) | |
| MDS NOS | 40 (23) | 64 (15) | |
| Systemic therapy before transplantation | <.001 | ||
| HMAs | 139 (79) | 323 (75) | |
| No HMAs | 15 (9) | 87 (21) | |
| Not reported | 22 (12) | 17 (4) | |
| Cytogenetic risk | <.001 | ||
| Monosomal karyotype | 33 (19) | 63 (15) | |
| Good | 83 (47) | 224 (52) | |
| Intermediate | 34 (19) | 80 (19) | |
| Poor/very poor | 20 (11) | 54 (12) | |
| Not reported | 6 (3) | 6 (1) | |
| Bone marrow blasts before transplantation, % | <.001 | ||
| <2 | 88 (50) | 212 (50) | |
| 2-5 | 35 (20) | 84 (20) | |
| 5-10 | 26 (15) | 97 (23) | |
| >10 | 9 (5) | 25 (6) | |
| Not reported | 18 (10) | 9 (2) | |
| IPSS-R score before transplantation | <.001 | ||
| Very low | 3 (2) | 35 (8) | |
| Low | 25 (14) | 123 (29) | |
| Intermediate | 44 (25) | 138 (32) | |
| High | 43 (24) | 93 (22) | |
| Very high | 43 (24) | 30 (7) | |
| Not reported | 18 (10) | 8 (2) | |
| Disease risk index | .08 | ||
| Intermediate | 59 (34) | 128 (30) | |
| High | 114 (65) | 298 (70) | |
| Not reported | 3 (1) | 1 (<1) | |
| Interval from diagnosis to transplantation, mo | <.04 | ||
| <6 | 37 (21) | 132 (31) | |
| 6-12 | 67 (38) | 131 (31) | |
| >12 | 72 (41) | 164 (38) | |
| Conditioning regimen* | NA | ||
| TBI + cyclophosphamide + fludarabine | 143 (81) | 6 (1) | |
| TBI + fludarabine | 11 (6) | 73 (17) | |
| Busulfan + fludarabine | 5 (3) | 187 (44) | |
| Fludarabine + melphalan | 10 (6) | 147 (35) | |
| TBI + busulfan + fludarabine | 7 (4) | 14 (3) | |
| Transplantation period | <.001 | ||
| 2012-2014 | 41 (23) | 179 (42) | |
| 2015-2017 | 135 (77) | 248 (58) | |
| Characteristic . | n (%) . | P . | |
|---|---|---|---|
| HLA-haploidentical donor (N = 176) . | HLA-matched unrelated donor (N = 427) . | ||
| Age, y | <.001 | ||
| 50-59 | 38 (22) | 41 (10) | |
| 60-69 | 103 (59) | 250 (59) | |
| 70-79 | 35 (20) | 136 (32) | |
| Sex | .24 | ||
| Male | 123 (70) | 277 (65) | |
| Female | 53 (30) | 150 (35) | |
| Race | <.001 | ||
| White | 141 (80) | 405 (95) | |
| Non-White | 32 (18) | 14 (3) | |
| Not reported | 3 (2) | 8 (2) | |
| HCT-CI | .30 | ||
| 0-2 | 76 (43) | 165 (39) | |
| 3+ | 100 (57) | 262 (61) | |
| KPS | .004 | ||
| 90-100 | 87 (49) | 177 (42) | |
| <90 | 82 (47) | 246 (57) | |
| Not reported | 7 (4) | 4 (< 1) | |
| CMV serostatus | .22 | ||
| Negative | 58 (33) | 173 (41) | |
| Positive | 117 (66) | 252 (59) | |
| Not reported | 1 (<1) | 2 (<1) | |
| Disease type | .44 | ||
| De novo MDS | 152 (86) | 358 (84) | |
| Therapy-related MDS | 24 (14) | 69 (16) | |
| WHO classification | .02 | ||
| RA/RARS/RCMD | 39 (22) | 134 (31) | |
| RAEB-1/RAEB-2 | 97 (55) | 229 (54) | |
| MDS NOS | 40 (23) | 64 (15) | |
| Systemic therapy before transplantation | <.001 | ||
| HMAs | 139 (79) | 323 (75) | |
| No HMAs | 15 (9) | 87 (21) | |
| Not reported | 22 (12) | 17 (4) | |
| Cytogenetic risk | <.001 | ||
| Monosomal karyotype | 33 (19) | 63 (15) | |
| Good | 83 (47) | 224 (52) | |
| Intermediate | 34 (19) | 80 (19) | |
| Poor/very poor | 20 (11) | 54 (12) | |
| Not reported | 6 (3) | 6 (1) | |
| Bone marrow blasts before transplantation, % | <.001 | ||
| <2 | 88 (50) | 212 (50) | |
| 2-5 | 35 (20) | 84 (20) | |
| 5-10 | 26 (15) | 97 (23) | |
| >10 | 9 (5) | 25 (6) | |
| Not reported | 18 (10) | 9 (2) | |
| IPSS-R score before transplantation | <.001 | ||
| Very low | 3 (2) | 35 (8) | |
| Low | 25 (14) | 123 (29) | |
| Intermediate | 44 (25) | 138 (32) | |
| High | 43 (24) | 93 (22) | |
| Very high | 43 (24) | 30 (7) | |
| Not reported | 18 (10) | 8 (2) | |
| Disease risk index | .08 | ||
| Intermediate | 59 (34) | 128 (30) | |
| High | 114 (65) | 298 (70) | |
| Not reported | 3 (1) | 1 (<1) | |
| Interval from diagnosis to transplantation, mo | <.04 | ||
| <6 | 37 (21) | 132 (31) | |
| 6-12 | 67 (38) | 131 (31) | |
| >12 | 72 (41) | 164 (38) | |
| Conditioning regimen* | NA | ||
| TBI + cyclophosphamide + fludarabine | 143 (81) | 6 (1) | |
| TBI + fludarabine | 11 (6) | 73 (17) | |
| Busulfan + fludarabine | 5 (3) | 187 (44) | |
| Fludarabine + melphalan | 10 (6) | 147 (35) | |
| TBI + busulfan + fludarabine | 7 (4) | 14 (3) | |
| Transplantation period | <.001 | ||
| 2012-2014 | 41 (23) | 179 (42) | |
| 2015-2017 | 135 (77) | 248 (58) | |
NA, not applicable (confounded with donor type); NOS, not otherwise specified; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; WHO, World Health Organization.
TBI dose ≤500 cGy.